Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.

[1]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[2]  A. Waters,et al.  Cognitive enhancement as a treatment for drug addictions , 2013, Neuropharmacology.

[3]  O. Bukstein,et al.  Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder , 2012, Expert opinion on pharmacotherapy.

[4]  G. Woody,et al.  Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. , 2012, Archives of general psychiatry.

[5]  E. Nunes,et al.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial , 2011, The Lancet.

[6]  G. Woody,et al.  Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available , 2010, Current psychiatry reports.

[7]  E. Krupitsky,et al.  Long-acting depot formulations of naltrexone for heroin dependence: a review , 2010, Current opinion in psychiatry.

[8]  Helge Waal,et al.  The pharmacological treatment of opioid addiction—a clinical perspective , 2010, European Journal of Clinical Pharmacology.

[9]  Peter N. Johnson,et al.  Lofexidine, an α2-Receptor Agonist for Opioid Detoxification , 2010, The Annals of pharmacotherapy.

[10]  R. Sinha,et al.  A stress-coping profile of opioid dependent individuals entering naltrexone treatment: a comparison with healthy controls. , 2009, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[11]  T. Kosten,et al.  Opioid dependence treatment: options in pharmacotherapy , 2009, Expert opinion on pharmacotherapy.

[12]  H. Kleber.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options , 2007, Dialogues in clinical neuroscience.

[13]  R. Sinha,et al.  Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment. , 2007, Experimental and clinical psychopharmacology.

[14]  R. Sinha,et al.  Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings , 2007, Psychopharmacology.

[15]  G. Woody,et al.  Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. , 2006, Journal of substance abuse treatment.

[16]  M. Gossop,et al.  Benzodiazepine co-dependence exacerbates the opiate withdrawal syndrome. , 2004, Drug and alcohol dependence.

[17]  G. Woody,et al.  Naltrexone for heroin dependence treatment in St. Petersburg, Russia. , 2004, Journal of substance abuse treatment.

[18]  W. Fals-Stewart,et al.  Behavioral family counseling and naltrexone for male opioid-dependent patients. , 2003, Journal of consulting and clinical psychology.

[19]  B. Rounsaville,et al.  Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. , 2001, Archives of general psychiatry.

[20]  Y. Shaham,et al.  Time-dependent changes in extinction behavior and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats , 2001, Psychopharmacology.

[21]  B. Rounsaville,et al.  Naltrexone and coping skills therapy for alcohol dependence. A controlled study. , 1992, Archives of general psychiatry.

[22]  S. Lundin,et al.  Administration of antidiuretic peptide (DDAVP) by way of suction de-epithelialised skin , 1991, The Lancet.

[23]  F. J. Evans,et al.  New Data from the Addiction Severity Index Reliability and Validity in Three Centers , 1985, The Journal of nervous and mental disease.

[24]  T. Kamarck,et al.  A global measure of perceived stress. , 1983, Journal of health and social behavior.

[25]  C. Spielberger,et al.  Emotions and Anxiety: New Concepts, Methods, and Applications , 1976 .

[26]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[27]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[28]  E. Nunes,et al.  [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial]. , 2012, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[29]  G. Woody,et al.  Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. , 1994, AIDS research and human retroviruses.

[30]  Linda C. Sobell,et al.  Timeline Follow-Back A Technique for Assessing Self-Reported Alcohol Consumption , 1992 .